13 results about "Serum triglycerides" patented technology

This invention discloses an oil composition with a balanced fatty acid ratio and lipid-lowering effects, and its applications. The oil composition comprises vegetable oil, probiotics, phospholipids from camellia seed cake, gelatin, and sodium alginate. It effectively reduces serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels while increasing high-density lipoprotein cholesterol levels, exhibiting a good lipid-lowering effect. Furthermore, when the oil composition is formulated into microcapsules, it exhibits good stability, encapsulation efficiency, and release rate. The oil composition also helps maintain the activity of probiotics, allowing for better preservation and efficacy. Based on this, this invention also provides a candy containing the oil composition, enriching the variety of products with lipid-lowering effects and promoting the development of lipid-lowering related products.

This invention relates to the application of PRMT4 inhibitors in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH), belonging to the field of fatty liver disease treatment technology. This invention is the first to discover that PRMT4 inhibitors can serve as a novel drug target for treating MASH. Cellular experiments show that PRMT4 inhibitors inhibit palmitic acid-induced hepatocyte steatosis. Animal experiments confirm that PRMT4 inhibitors can improve hepatic fat deposition, inflammatory response, hepatocyte damage, fibrosis, and insulin resistance in high-fat fed mice, and reduce liver tissue and serum triglyceride and transaminase levels. This invention finds that PRMT4 inhibitors mainly inhibit the activation of YAP, a key transcriptional activator involved in lipid and inflammatory metabolism, and the expression of its downstream target genes. Therefore, PRMT4 inhibitors can be used to prepare drugs for treating MASH, with definite and significant efficacy, and have promising medical application prospects.

The application belongs to the field of biological medicine research and development, and particularly relates to application of umbilical cord mesenchymal stem cell-derived vascular endothelial precursor cells in preparation of medicines for preventing and treating atherosclerosis. By interfering with expression of related factors in a pyroptosis inflammatory signaling pathway of NLRP3, ASC, Caspase-1, GSDMD, IL-1β and IL-18 at a transcription and protein level, the serum triglyceride concentration, total cholesterol concentration and low-density lipoprotein concentration can be reduced, the serum oxidized low-density lipoprotein and oxygen free radical concentration can be reduced, the serum high-density lipoprotein concentration can be increased, and the atherosclerotic plaque area can be reduced and cell apoptosis in the atheromatous plaque can be inhibited.

The invention relates to a compound 7-3A for reducing blood fat and application of the compound 7-3A. The structure of the compound 7-3A is shown as a formula (1). Formula (1). The invention also relates to the following application of the compound as shown in the formula (1): (1) preparing a medicine or preparation for controlling and / or reducing the body weight of a hyperlipidemia patient; (2) preparing medicines or preparations for controlling and / or reducing the serum triglyceride (TG) level of hyperlipidemia patients; and (3) preparing a medicine or a preparation for inhibiting very low density lipoprotein (VLDL) of hyperlipidemia patients from transferring endogenous triglyceride.

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

The invention discloses a composition for diabetes. The composition comprises carbohydrate, dietary fiber, protein, grease and trace elements. The composition can reduce fasting blood glucose levels, reduce serum triglyceride and total cholesterol levels, increase high density lipoprotein levels and improve insulin tolerance in diabetic patients. Therefore, the composition is used for preparing medicines or health-care products for treating and / or preventing diabetes mellitus.

The invention belongs to the technical field of medicines, and particularly relates to a monascus fermentation composition, a fermentation method and application of the monascus fermentation composition. The application firstly discloses a monascus fermentation process, the achilleone is added in the monascus fermentation process for co-fermentation with a basic culture medium for the first time, and the content of monascorubin and monacolin K in the obtained fermentation extract is remarkably increased. Meanwhile, the achilleone is added into the fermentation extract to form the fermentation composition, so that the blood fat reducing effect of the composition can be further improved. Model animal experiments prove that when the mass ratio of the fermentation extract to the yarrow ketone is 20: 1, the improvement effect on model animal serum triglyceride is optimal.

The invention discloses an application of a composition in preparation of a synergist of a medicine for treating atherosclerosis, the composition can effectively enhance the treatment effect of the medicine for treating atherosclerosis through reasonable compatibility of all components, improve the effect of the medicine for treating atherosclerosis in multiple aspects, block the progress of the disease course, reduce the treatment cost and improve the treatment effect of the medicine for treating atherosclerosis. Comprising the following steps: improving indexes such as aorta plaque area, vasomotor inner diameter difference, intima-media thickness, serum triglyceride, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol content, homocysteine content in blood and the like in atherosclerosis, and reducing the dosage of medicines for treating atherosclerosis; the prescription is safe and reliable without toxic and side effects on human bodies.

The invention provides application of PCTR1 in preparation of drugs for preventing or treating metabolic dysfunction related diseases. Experimental results show that the PCTR1 can relieve HFD-induced obesity, obviously reduce fat accumulation quality, improve lipid metabolism disorder, reduce serum triglyceride and total cholesterol levels, increase insulin sensitivity, improve the blood sugar regulation capacity of an organism and reduce the fatty liver degree, and has the potential of being developed into drugs for treating metabolic dysfunction related diseases.

This invention belongs to the field of traditional Chinese medicine preparations, specifically relating to a traditional Chinese medicine composition for weight loss, its preparation method, and its application. The traditional Chinese medicine composition of this invention is made from the following raw materials in parts by weight: 15-25 parts Angelica sinensis, 8-12 parts Astragalus membranaceus, 8-12 parts Citrus reticulata peel, and 8-12 parts Nelumbo nucifera leaf. In this invention, Angelica sinensis is the principal herb, promoting blood circulation and unblocking collaterals; Astragalus membranaceus is the assistant herb, tonifying qi and promoting digestion; Citrus reticulata peel is the adjuvant herb, regulating qi and resolving phlegm; and Nelumbo nucifera leaf is the guiding herb, clearing heat and promoting diuresis. The entire formula works synergistically to resolve phlegm, promote diuresis, strengthen the spleen, and soothe the liver. Animal experiments have shown that the composition of this invention can significantly reduce weight gain, fat accumulation, and liver fat content in obese mice, improve oral glucose tolerance, and reduce serum triglyceride and low-density lipoprotein cholesterol levels. At the same time, it can significantly restore the diversity of intestinal flora α, increase the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, effectively improve the intestinal flora disorder induced by a high-fat diet in mice, and the remodeled intestinal flora can play a role in weight loss. Thus, this invention provides a safe, effective, and palatable new traditional Chinese medicine compound solution for metabolic disorders and intestinal microecological imbalance.

This invention relates to the field of biomedical technology, specifically to a drug for treating and preventing metabolic obesity caused by a high-fat diet. This invention provides a method to reduce... C2orf74 The use of compositions that reduce gene expression levels in the preparation of medicaments for the prevention and / or treatment of obesity, by utilizing the reduction of gene expression levels. C2orf74 In situ injection of a combination of gene expression levels into the testes of animals can prevent and treat obesity caused by a high-fat diet. Specifically, it can alleviate the obesity phenotype caused by a high-fat diet, including reducing weight gain, reducing fat accumulation, lowering serum triglyceride and cholesterol levels, improving blood glucose regulation and enhancing insulin sensitivity; and reducing the degree of fatty liver degeneration.

The invention discloses application of dehydrocostus lactone and a medicine for treating steatohepatitis, relates to the technical field of biological medicines, and solves the problems that in the prior art, the application scene of the dehydrocostus lactone is limited, and the application of the dehydrocostus lactone in a complex pathological environment of metabolic dysfunction related steatohepatitis has a technical blank. Dehydrocostus lactone can reduce lipid accumulation, inflammation and fibrosis in liver cells; the weight, liver weight, serum triglyceride content, serum total cholesterol content and insulin resistance level of animals with steatohepatitis are reduced; the content of serum glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, tumor necrosis factor alpha, interleukin 1beta, malondialdehyde and bivalent ferrous ions is reduced, and the content of serum glutathione is increased; the compound can regulate and control lipid metabolism and mitochondrial energy metabolism pathways, reprograms fatty degeneration liver cell energy metabolism phenotypes, and is applied to preparation of drugs for treating steatohepatitis, ferroptosis inhibitors and glutamic oxalacetic transaminase and / or glutamic-pyruvic transaminase inhibitors.

The application discloses application of a Solanum torvum extract in preparation of a medicine for preventing and treating non-alcoholic fatty liver and indications thereof, and the Solanum torvum extract comprises one or both of a Solanum torvum water extract and a Solanum torvum alcohol extract; the application is proved by experiments that the Solanum torvum alcohol extract can obviously reduce the weight of a non-alcoholic fatty liver NAFLD mouse; the Solanum torvum water extract can obviously reduce the inguinal white fat; the Solanum torvum extract can obviously reduce a liver weight / body weight index, a liver triglyceride (TG) content, liver lipid deposition, and liver function damage indexes, i.e., glutamic-oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT). The Solanum torvum extract can also reduce serum triglyceride (TG) and cholesterol (TC) levels of the mouse, improve lipid levels, and therefore has an important role in treating non-alcoholic fatty liver.